EQS-Ad-hoc: SMA Solar Technology AG / Key word(s): Quarter Results/Change in Forecast SMA Solar Technology AG expects very positive first half of 2023 and again increases full-year guidance 2023 Niestetal, June 23, 2023 - The Managing Board of SMA Solar Technology AG (SMA/ISIN: DE000A0DJ6J9/FWB: S92) expects sales of EUR 770 to 780 million (HY1 2022: EUR 472 million) and operating earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 120 to 130 million (HY1 2022: EUR 16 million) for the first half of 2023. The reason for this, following the already positive Q1, is a strong Q2 above plan with sales expected to reach EUR 400 to 410 million (Q2 2022: EUR 251 million) and EBITDA expected to be EUR 60 to 70 million (Q2 2022: EUR 1 million). On this basis, the Managing Board is adjusting the full year guidance for 2023 and now expects annual sales of EUR 1,700 to 1,850 million (previously: EUR 1,450 to 1,600 million) and EBITDA of EUR 230 to 270 million (previously: EUR 135 to 175 million). The reason for the better-than-planned performance and the more positive outlook is a significant increase in delivery capabilities due to faster improvements in material supplies from the supplier side and an improved earnings contribution from all segments. The final figures for the 1st half of 2023 will be published on August 10, 2023.
Contact: Viona Brandt Investor Relations Tel.: +49 175 93 93 320 End of Inside Information
23-Jun-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | SMA Solar Technology AG |
Sonnenallee 1 | |
34266 Niestetal | |
Germany | |
Phone: | +49 (0)561 / 9522 - 0 |
Fax: | +49 (0)561 / 9522 - 100 |
E-mail: | info@sma.de |
Internet: | http://www.sma.de |
ISIN: | DE000A0DJ6J9 |
WKN: | A0DJ6J |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1664735 |
End of Announcement | EQS News Service |
|
1664735 23-Jun-2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.